Sanofi SA
SASY.PA- Latest Trade
- trading higher89.79EUR
- 0.24
- 0.27%
- As of Jan 30 2023. Values delayed up to 15 minutes
- Day Range
- 88.89 - 90.24
- 52-Week Range
- 76.45 - 106.66
- Previous Close
- 89.55
- Open
- 89.12
- Volume
- 1,235,322.00
- 3 Month Average Trading Volume
- 37.64
- Shares Out (Mil)
- 1,252.00
- Market Cap
- 112,907.80
- Forward P/E
- 10.85
- Dividend Yield
- 3.70
Key Statistics
2.11111111 mean rating - 27 analysts
- P/E Excl. Extra Items (TTM)
- 17.61
- Price To Sales (TTM)
- 2.55
- Price To Book (Quarterly)
- 0.00
- Price To Cash Flow (Per Share TTM)
- 13.82
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- 0.00
- Return On Equity (TTM)
- 0.00
2021 (millions USD)
About Sanofi SA (SASY.PA)
Company Information
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
Address
54 rue la BoetiePARIS,
75008
France
Industry
Biotechnology & Drugs
Executive Leadership
- Serge Weinberg
- Independent Chairman of the Board
- Paul Hudson
- Chief Executive Officer, Member of the Executive Committee, Director
- Jean Baptiste Chasseloup De Chatillon
- Chief Financial Officer, Executive Vice President, Member of the Executive Committee
- Natalie Bickford
- Chief People Officer, Executive Vice President, Member of the Executive Committee
- Roy Papatheodorou
- Executive Vice President, General Counsel and Head of Legal, Ethics and Business Integrity, Member of the Executive Board
- Olivier Charmeil
- Executive Vice President - General Medicines, Member of the Executive Committee
- Brendan O' Callaghan
- Executive Vice President, Global Head of Industrial Affairs, Member of the Executive Board
- John C. Reed
- Executive Vice President - Global Head of Research and Development, Member of the Executive Committee
- Arnaud Robert
- Executive Vice President, Chief Digital Officer, Member of the Executive Committee
- William J. Sibold
- Executive Vice President - Sanofi Genzyme, Member of the Executive Committee
- Thomas Triomphe
- Executive Vice President - Head of Sanofi Pasteur, Member of the Executive Committee
- Julie Van Ongevalle
- Executive Vice President - Consumer Healthcare, Member of the Executive Committee
- Christophe Babule
- Director
- Wolfgang Laux
- Director, Employee Representative
- Barbara Lavernos
- Director
- Tran Yann
- Director, Employee Representative
- Rachel Duan
- Independent Director
- Lise Kingo
- Independent Director
- Patrick Kron
- Independent Director
- Fabienne Lecorvaisier
- Independent Director
- Melanie Lee
- Independent Director
- Gilles Schnepp
- Independent Director
- Diane Souza
- Independent Director
- Thomas Sudhof
- Independent Director
Latest News
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,922.50 | 0.36% |
| Copper | 781.95 | 0.17% |
| Brent Crude Oil | 85.59 | 1.23% |
| CBOT Soybeans | 1,533.50 | 1.59% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,017.77 | 1.30% |
| Euro STOXX 50 | 4,158.63 | 0.46% |
| FTSE 100 | 7,784.87 | 0.25% |
| Nikkei 225 | 27,433.40 | -- |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes